GlassScriptPhysician profile
Renata Castelo
NPI 1831750249
$3,031.83
in general payments reported to CMS, 2019-2025
38 companies · $1,209 in 2025
The $1,209 reported for 2025 was more than what 91% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $46.00 · 2022: $177 · 2023: $751 · 2024: $849 · 2025: $1,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,723 · Education: $85.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,722.64 |
| Education | $85.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $392.87 | 2022-2025 | Enhertu, Datroway, Lynparza |
| Daiichi Sankyo INC. | $279.38 | 2021-2025 | Enhertu, Datroway |
| Glaxosmithkline, LLC. | $272.99 | 2023-2025 | Jemperli, Ojjaara |
| E.R. Squibb & Sons, L.L.C. | $226.32 | 2023-2025 | Reblozyl |
| Janssen Biotech, INC. | $129.58 | 2023-2025 | Erleada, Darzalex, Akeega |
| Immunogen, INC. | $124.04 | 2023 | Elahere |
| Organogenesis INC. | $120.03 | 2022 | |
| Novartis Pharmaceuticals Corporation | $114.76 | 2024 | |
| Genmab U.S., INC. | $108.28 | 2024-2025 | Tivdak, Epkinly |
| Astellas Pharma US INC | $107.90 | 2025 | Xtandi, Padcev, Veozah |
| Merck Sharp & Dohme LLC | $101.32 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $98.71 | 2024-2025 | Fruzaqla, Alunbrig, Iclusig |
| Tempus Ai, INC | $95.40 | 2024 | |
| Abbvie INC. | $89.36 | 2024-2025 | |
| Integra Lifesciences Corporation | $67.18 | 2023 | Cusa Clarity, Codman Hakim, Duraseal Exact Spinal Sealant System |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $65.00 | 2023 | Tivdak |
| Eisai INC. | $47.64 | 2023-2024 | |
| Genzyme Corporation | $43.21 | 2025 | |
| Lilly USA, LLC | $42.54 | 2023-2024 | Verzenio, Jaypirca |
| Caris Mpi, INC. | $33.06 | 2025 | Mi Cancer Seek |
| Pharmaessentia USA Corporation | $32.46 | 2025 | Besremi |
| Tersera Therapeutics LLC | $31.64 | 2025 | Quzyttir |
| Dendreon Pharmaceuticals LLC | $31.54 | 2025 | Provenge |
| Regeneron Healthcare Solutions, INC. | $31.35 | 2025 | Libtayo |
| Exelixis INC. | $31.07 | 2025 | Cabometyx |
| Kite Pharma, INC. | $30.90 | 2024 | Yescarta |
| Emd Serono, INC. | $29.67 | 2025 | |
| Tactile Systems Technology INC | $28.65 | 2023 | Flexitouch Plus, Entre Plus |
| Foundation Medicine, INC. | $28.00 | 2023 | |
| Sobi, INC | $26.77 | 2025 | |
| Incyte Corporation | $24.85 | 2025 | Monjuvi |
| Progenics Pharmaceuticals, INC. | $24.44 | 2024 | |
| Ethicon US, LLC | $22.63 | 2023 | Enseal |
| Pharmaand Gmbh | $22.01 | 2025 | Rubraca |
| Tolmar, INC. | $22.01 | 2025 | Rubraca |
| Bayer Healthcare Pharmaceuticals INC. | $20.39 | 2025 | |
| Pfizer INC. | $18.83 | 2024 | |
| Servier Pharmaceuticals LLC | $15.05 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renata Castelo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.